CAS: 59-41-6; Bretylium

专利信息

专利号:US-10925977-B2
优先权日:2006-10-05
标 题 :Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
发明人：YANG DAVID J; YU DONGFANG; THOMPSON ANDREW S
权利人:YANG DAVID J; YU DONGFANG; THOMPSON ANDREW S; CEIL POINT LLC; UNIV TEXAS
摘要:Novel methods of synthesis of chelator-targeting ligand conjugates, compositions comprising such conjugates, and therapeutic and diagnostic applications of such conjugates are disclosed. The compositions include chelator-targeting ligand conjugates optionally chelated to one or more metal ions. Methods of synthesizing these compositions in high purity are also presented. Also disclosed are methods of imaging, treating and diagnosing disease in a subject using these novel compositions, such as methods of imaging a tumor within a subject and methods of diagnosing myocardial ischemia.

专利号:US-RE41998-E
优先权日:1990-02-26
标题 :Compositions and methods of treatment of sympathetically maintained pain
发明人：CAMPBELL JAMES N
权利人:ARCLON THERAPEUTICS INC
摘要:Sympathetically maintained pain is treated topically by administering to the site where sympathetically maintained pain is present an α-1-adrenergic antagonist, α-2-adrenergic agonist, or other drug that depletes or blocks synthesis of sympathetic norepinephrine, known collectively as sympatholytic agents. Chemical formulas for several sympatholytic agents are given.

专利号:US-5447947-A
优先权日:1990-02-26
标 题:Compositions and methods of treatment of sympathetically maintained pain
发明人：CAMPBELL JAMES N
权利人:ARC 1
摘要:Sympathetically maintained pain is treated topically by administering to the site where sympathetically maintained pain is present an α-adrenergic antagonist, α-1-adrenergic antagonist, α2 adrenergic agonist, or other drug that depletes or blocks synthesis of sympathetic norepinephrine. Examples demonstrate relief of pain by application of phentolamine or clonidine.

专利号:US-7329767-B2
优先权日:2003-10-03
标 题:Conjugated dienamides, methods of production thereof, compositions containing same and uses thereof
发明人：DEWIS MARK L; JOHN THUMPLASSERIL V; ECKERT MARKUS A; COLSTEE JAN HERMAN; DA COSTA NEIL C; PEI TAO
权利人:INT FLAVORS & FRAGRANCES INC
摘要:Described are mixtures of at least four of the alkadienamides defined according to the structure: n nwherein R represents C 1 -C 2 n-alkyl; R 1 is 2-methyl-1-propyl and R 2 is hydrogen, or R 1 and R 2 taken together is a moiety having the formulan n nwherein n is 4 or 5, or compositions containing substantial concentrations of such mixtures, prepared according to novel processes: (a) extraction of a ground substantially dried fruit of one of the Piper species, Piper longum Linn or Piper peepuloides ; (b) natural product-forming synthesis; or (c) synthetic product-forming synthesis. Also described are uses of the thus-formed products for augmenting, enhancing or imparting an aroma, taste, chemesthetic effect and/or antibacterial effect in or to a consumable material and/or in the oral cavity and/or on the mammalian epidermis.

专利号:US-6130240-A
优先权日:1993-06-16
标题 :Compound for treatment of cardiac arrhythmia, synthesis, and methods of use
发明人：DRUZGALA PASCAL
权利人:ARYX THERAPEUTICS INC
摘要:Described is a novel compound and method, useful for treatment of cardiac arrhythmias, especially useful in patients with congestive heart failure (CHF). A process for synthesizing the novel compound is also described.

专利号:US-6316487-B1
优先权日:1993-06-16
标 题:Compounds for treatment of cardiac arrhythmia synthesis, and methods of use
发明人：DRUZGALA PASCAL; MILNER PETER G
权利人:ARYX THERAPEUTICS
摘要:The subject invention pertains to novel compounds, and compositions comprising the compounds, for the treatment of cardiac arrhythmias. The subject invention further concerns a method of making the novel compounds. The novel compounds are rapidly metabolized analogs of amiodarone, having the distinct and advantageous characteristic of being metabolized to a less lipophilic compound. The new compounds can have particular utility for treating life-threatening ventricular tachyarrhythmias, especially in patients with congestive heart failure (CHF). The product can also provide effective management for ventricular arrhythmias and supraventricular arrhythmias, including atrial fibrillation and re-entrant tachyarrhythmias involving accessory pathways.